Organic Active Ingredients TRIZ Cases

A triple combination therapy using anti-alpha4beta7 antibody, TNF antagonist, and immunomodulator to achieve endoscopic remission.

Fluidized bed dry milling reduces particle size while avoiding contamination and caking issues that limit conventional wet or mechanical grinding methods.

PIKfyve inhibitors restore MHC-I surface expression on cancer cells to enhance CD8+ T cell recognition.

Targeting aberrant m6A regulators inhibits tumor growth and alleviates pelvic pressure in uterine fibroids.

4-Hydroxytestosterone binds androgen receptors to treat breast cancer without aromatization.

Short peptides replace large antibodies to improve tissue penetration and reduce immune response while maintaining specific binding.

Intravitreal fludrocortisone treats geographic atrophy while minimizing systemic side effects.

Fatty acid ionic liquid and divalent alcohol dissolve poorly soluble pramipexole hydrochloride, preventing precipitation in the adhesive matrix.

A direct-acting subcutaneous P2Y12 receptor antagonist provides rapid platelet aggregation inhibition without metabolic activation.

Mitochondrial iron chelators regulate iron loading to alleviate dysfunction, addressing limited efficacy in inhibiting chronic inflammation.

Engineered RNA switches secondary structures via strand displacement, preventing off-target effects from premature actuator recognition.

A pharmaceutical composition combining unsaturated fatty acids, nitric oxide releasing compounds, anti-glycation agents, and colostrum to enhance physiological function.

Radiofrequency heating bonds powder blends at low compression to resolve friability issues in orally disintegrating tablet production.

Enzyme complex hydrolysis releases soluble fibers from insoluble structures, improving bioavailability and reducing gastrointestinal discomfort.

Selective P2X3 modulation provides pain relief while preserving taste response and cough reflex.

L-cysteine sucking tablets neutralize acetaldehyde in the oral cavity, resolving low long-term withdrawal success rates.

Benzotriazole derivatives modulate CB1 receptors to treat obesity and neurological disorders.

Hybrid molecules inhibit lipid peroxidation and prevent ROS-dependent cell death in mitochondrial disorders.

A substituted pyridone-pyrimidine derivative acts as a KRAS G12C inhibitor.

A glycosaminoglycan derivative uses a covalent spacer to regulate drug dissociation rates for targeted therapeutic delivery.

Water-soluble hydroxyalkyl cellulose film flakes deliver blue-violet pigments to tooth surfaces.

Modified MTDs bypass endocytic pathways to deliver biologically active molecules into deep tissues while maintaining molecular activity.

Epoxyketone compounds resolve specificity limitations by inhibiting chymotrypsin-like proteases via covalent bonding.

Sulfobutyl ether cyclodextrin salt forms the inner water phase of liposomes to encapsulate anti-tumor drugs.

Replacing polyhydric alcohols with amines prevents esterification reactions, maintaining storage stability while ensuring high drug absorbability.

Novel compounds inhibit genotoxic stress-induced IKK/NF-kB pathways via specific protein-protein interaction interference.

Capillary electrophoresis detects degradation products in buffered pentosan polysulfate formulations, ensuring stability without refrigeration.

Allosteric binding of a heteroarylamide compound prevents drug resistance in Bcr-Abl kinase inhibition.

Nucleophilic warheads form covalent bonds with sulfenic acid-modified cysteine residues to avoid nonspecific reactivity with cellular thiols.

A nutritional adjuvant containing baicalin and baicalein stimulates feed conversion and appetite in farm animals.

Switching crystallization solvents from organics to water eliminates genotoxic ester impurities while maintaining high yield.

An implantable poly(D,L-lactide) depot provides sustained clonidine release, reducing systemic side effects while treating degenerative disc inflammation.

Targeting TAHO polypeptides resolves the contradiction between broad treatment coverage and tissue specificity in hematopoietic cancer therapy.

Shortened poly-N-acetylglucosamine nanofibers stimulate defensin expression and secretion to boost innate immunity.

Aliphatic tail structures reduce molecular weight and eliminate bile acids transport inhibition to prevent hepatotoxicity in type 2 diabetes treatment.

Optically clear GRAS cyanine dyes activate under low-intensity light to eliminate bacterial biofilms without the toxicity of conventional photosensitizers.

Topical casein kinase 1 inhibitors reduce sebaceous gland size and sebum production while extending the anagen phase to promote hair growth.

Specific substituent patterns on the purine ring enhance anti-cancer potency while reducing toxicity and treatment costs.

Selective M1 receptor agonists treat psychosis without peripheral cholinergic side effects.

Chiral chromatography resolves Δ9-THC enantiomers to overcome low purity in conventional extraction, achieving pharmaceutical-grade separation.

Co-administering oral docetaxel with a CYP3A inhibitor blocks metabolic clearance, reducing toxicity and eliminating dexamethasone premedication.

A phosphate salt of a PDE10 inhibitor provides high solubility and intrinsic dissolution rate for pharmaceutical formulations.

Ultrasonic vibration disperses antibiotics locally, minimizing systemic side effects and tissue dehydration while maintaining effective infection prevention.